Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer

It has been over three decades since the hepatocyte growth factor (HGF) ligand and its receptor MET proto-oncogene (MET) pathway was established as promoting cancer growth and metastasis. MET exon 14 skipping (METex14) alterations occur in 3–4% of all non-small cell lung cancer (NSCLC) patients, typ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Lingzhi, Zhang, Jianjun, Heymach, John V., Le, Xiuning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890719/
https://www.ncbi.nlm.nih.gov/pubmed/33643443
http://dx.doi.org/10.1177/1758835921992976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890719/
https://www.ncbi.nlm.nih.gov/pubmed/33643443
http://dx.doi.org/10.1177/1758835921992976

Ejemplares similares